Clinical Efficacy of Inferior Turbinate Outfracture Combined with Low-Temperature Plasma Radiofrequency Ablation in Obese Patients with Obstructive Sleep Apnea-Hypopnea Syndrome Complicated with Nasal Obstruction
摘要
To evaluate the clinical efficacy of inferior turbinate outfracture combined with low-temperature plasma radiofrequency ablation on sleep quality, nasal ventilation function, tolerance to nasal continuous positive airway pressure (nCPAP) therapy and body mass index (BMI) in obese patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) (BMI ≥ 28.0 kg/m²). A total of 40 obese OSAHS patients complicated with bilateral inferior turbinate hypertrophy underwent inferior turbinate outfracture combined with low-temperature plasma radiofrequency ablation under general anesthesia. Before surgery, as well as at 1 month, 6 months and 1 year after surgery, polysomnography (PSG) was used to record the apnea-hypopnea index (AHI), and rhinomanometry was adopted to measure nasal airway resistance. The Epworth Sleepiness Scale (ESS) and Visual Analogue Scale (VAS) were applied to assess daytime sleepiness and tolerance to nCPAP therapy, and changes in patients’ BMI were monitored simultaneously. The AHI and BMI values at 1 month, 6 months and 1 year postoperatively were significantly lower than those before surgery (P < 0.05), and the two indicators were further decreased at 1 year after surgery compared with 1 month after surgery (P < 0.05). Nasal airway resistance at all postoperative time points was markedly reduced compared with the baseline and remained stable within one year after operation (P < 0.05). The VAS scores for nCPAP tolerance were significantly increased after surgery (P < 0.05). In addition, the ESS scores at each follow-up time point were obviously decreased relative to preoperative levels (P < 0.05), with further improvement at 6 months after surgery in comparison with 1 month after surgery (P < 0.05). Inferior turbinate outfracture combined with low-temperature plasma radiofrequency ablation can durably and effectively reduce nasal airway resistance, improve patients’ compliance with nCPAP therapy, significantly optimize sleep quality and assist patients in losing weight among obese OSAHS patients, with stable clinical efficacy.